Pharmaceutical Business Review
Anonymous User | Login

GlaxoSmithKline Discontinues Development Of Remogliflozin

Published: 03-Jul-2009

Discontinuation as a result of evaluating circumstances, including the development status of SGLT2 inhibitors by competitors

Kissei Pharmaceutical announced that GlaxoSmithKline has discontinued the development of the novel agent for diabetes, remogliflozin (KGT-1681). It was as a result of evaluating circumstances including the development status of SGLT2 inhibitors by competitors.

Kissei has discovered the SGLT2 inhibitor, remogliflozin and the SGLT1 inhibitor, KGA-3235 for diabetes, and licensed the development and marketing right of the agents in the US and Europe to GlaxoSmithKline.

Remogliflozin is in the stage of phase-II clinical studies, whereas KGA-3235 is in the stage of phase-I clinical study.

With regard to the development of SGLT inhibitors, GlaxoSmithKline has decided to continue to develop KGA-3235.

Share

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Adis

Independently Evaluated Drug Information ...

Almac

Drug Development Solutions ...

Altiora

To Strive for the Highest ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

GRACO's New FDA Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New Hydra-Clean

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New 1590 & 3150 Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Customer Testimonial – Astra Zeneca

From the control room to the downstream processing area and with an eye on utilities servi ...

Hygienic Processing

From the control room to the downstream processing area and with an eye on utilities servi ...

Related Companies

Taisho Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Co., Ltd. (Taisho) is a Japan-based pharmaceutical company. Taish ...

AstraZeneca PLC

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

Schering-Plough Corporation

Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on di ...

Amgen Inc.

Amgen Inc. (Amgen) is a biotechnology company that is focused on the discovery, develo ...

Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical Co., Ltd. (Kissei Pharmaceutical) is a Japan-based company that i ...

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address